Teva Gains FDA Approval for Monthly Olanzapine Injection to Treat Schizophrenia
The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries' (TEVA) Weltruza, an ultra-long-acting injectable antipsychotic containing olanzapine for the treatment of schizophrenia. Administered once a month, the medication will be available in three different doses to provide flexibility in patient care. Teva highlighted that this approval marks a significant advancement in long-term treatment options for individuals with schizophrenia who may benefit from reduced dosing frequency and improved adherence. The drug is part of Teva's broader strategy to expand its portfolio in mental health treatments, leveraging the well-established therapeutic profile of olanzapine while offering an innovative delivery method. The approval could enhance Teva’s market position within the antipsychotic segment by addressing unmet medical needs and potentially increasing patient compliance through a monthly dosing regimen.
Tickers: $TEVA